Alzheimer’s Disease: Significant Benefit from the Yeast-Based Models
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24129791 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Khoren K Epremyan und 2 weiteren Autor:innen. Beteiligte Einrichtung: A.N. Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Leninsky Ave. 33/2, 119071 Moscow, Russia. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation, Russian Foundation for Basic Research.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is an age-related, multifaceted neurological disorder associated with accumulation of aggregated proteins (amyloid Aβ and hyperphosphorylated tau), loss of synapses and neurons, and alterations in microglia. AD was recognized by the World Health Organization as a global public health priority. The pursuit of a better understanding of AD forced researchers to pay attention to well-defined single-celled yeasts. Yeasts, despite obvious limitations in application to neuroscience, show high preservation of basic biological processes with all eukaryotic organisms and offer great advantages over other disease models due to the simplicity, high growth rates on low-cost substrates, relatively simple genetic manipulations, the large knowledge base and data collections, and availability of an unprecedented amount of genomic and proteomic toolboxes and high-throughput screening techniques, inaccessible to higher organisms. Research reviewed above clearly indicates that yeast models, together with other, more simple eukaryotic models including animal models, C. elegans and Drosophila, significantly contributed to understanding Aβ and tau biology. These models allowed high throughput screening of factors and drugs that interfere with Aβ oligomerization, aggregation and toxicity, and tau hyperphosphorylation. In the future, yeast models will remain relevant, with a focus on creating novel high throughput systems to facilitate the identification of the earliest AD biomarkers among different cellular networks in order to achieve the main goal—to develop new promising therapeutic strategies to treat or prevent the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- A.N. Bach Institute of Biochemistry, Research Center of Biotechnology of the Russian Academy of Sciences, Leninsky Ave. 33/2, 119071 Moscow, Russia.
Förderung
- Ministry of Science and Higher Education of the Russian Federation
- Russian Foundation for Basic Research
Zitieren
APA
Epremyan, K. K., Mamaev, D. V., & Zvyagilskaya, R. A. (2023). Alzheimer’s Disease: Significant Benefit from the Yeast-Based Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24129791
Vancouver
Epremyan KK, Mamaev DV, Zvyagilskaya RA. Alzheimer’s Disease: Significant Benefit from the Yeast-Based Models. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24129791
BibTeX
@article{Epremyan2023,
author = {Epremyan, Khoren K and Mamaev, Dmitry V and Zvyagilskaya, Renata A},
title = {Alzheimer’s Disease: Significant Benefit from the Yeast-Based Models},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24129791}
}
EUVIMED